GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » ROE %

Alto Neuroscience (Alto Neuroscience) ROE % : -88.39% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Alto Neuroscience's annualized net income for the quarter that ended in Mar. 2024 was $-53.67 Mil. Alto Neuroscience's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $60.72 Mil. Therefore, Alto Neuroscience's annualized ROE % for the quarter that ended in Mar. 2024 was -88.39%.

The historical rank and industry rank for Alto Neuroscience's ROE % or its related term are showing as below:

ANRO' s ROE % Range Over the Past 10 Years
Min: -122.49   Med: 0   Max: 0
Current: -122.49

ANRO's ROE % is ranked worse than
80.88% of 1360 companies
in the Biotechnology industry
Industry Median: -43.445 vs ANRO: -122.49

Alto Neuroscience ROE % Historical Data

The historical data trend for Alto Neuroscience's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience ROE % Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
ROE %
- - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial - - - - -88.39

Competitive Comparison of Alto Neuroscience's ROE %

For the Biotechnology subindustry, Alto Neuroscience's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's ROE % distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's ROE % falls into.



Alto Neuroscience ROE % Calculation

Alto Neuroscience's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-36.305/( (-38.406+-71.672)/ 2 )
=-36.305/-55.039
=N/A %

Alto Neuroscience's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-53.668/( (-71.672+193.104)/ 2 )
=-53.668/60.716
=-88.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Alto Neuroscience  (NYSE:ANRO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-53.668/60.716
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-53.668 / 0)*(0 / 148.275)*(148.275 / 60.716)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*2.4421
=ROA %*Equity Multiplier
=N/A %*2.4421
=-88.39 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-53.668/60.716
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-53.668 / -53.668) * (-53.668 / -57.544) * (-57.544 / 0) * (0 / 148.275) * (148.275 / 60.716)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9326 * N/A % * 0 * 2.4421
=-88.39 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Alto Neuroscience ROE % Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus